Trillium Announces Partial Exercise of Over-Allotment Option
TORONTO, ONTARIO--(Marketwired - Jun 28, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the underwriters of its recent …